Beta defensin-3 engineered epidermis shows highly protective effect for bacterial infection

Area of Science:

• Biochemistry
• Dermatology
• Gene Therapy

Background:

• Defensins are antimicrobial peptides with broad-spectrum activity.
• Human beta-defensin 3 (HBD3) is a key component of the innate immune system.
• Bacterial infections pose a significant threat to compromised skin, such as ulcers.

Purpose of the Study:

• To investigate the efficacy of epidermis engineered to express HBD3 for combating bacterial infections.
• To evaluate the localization and antimicrobial activity of HBD3 in engineered skin.
• To explore the potential of HBD3 gene therapy for intractable infectious diseases.

Main Methods:

• Localization studies of HBD3 in engineered epidermis.
• Establishment of a keratinocyte cell line stably expressing HBD3.
• Antimicrobial assays using HBD3-expressing cell culture medium and engineered epidermal sheets grafted onto nude rat wounds.
• Measurement of HBD3 mRNA levels in skin ulcer biopsies.

Main Results:

• HBD3 was localized to intercellular spaces and lamellar bodies in the upper epidermis.
• Culture medium from HBD3-expressing keratinocytes exhibited antibacterial activity.
• HBD3-engineered epidermis demonstrated significant antimicrobial effects in a wound model.
• Epidermal samples from skin ulcers showed elevated HBD3 transcript levels compared to control skin.

Conclusions:

• Engineered epidermis expressing HBD3 possesses significant antimicrobial properties.
• The localization and activity of HBD3 suggest its role in combating epidermal infections.
• HBD3 gene therapy represents a potential strategy for treating intractable skin infections.